Phase II-III study to assess the efficacy and safety of subcutaneous cluster-immunotherapy in patients suffering from birch pollen allergy
Latest Information Update: 11 Apr 2023
At a glance
- Drugs Birch cluster immunotherapy-Immunotek/ROXALL-Medizin (Primary)
- Indications Allergic rhinitis; Allergic rhinoconjunctivitis
- Focus Therapeutic Use
- Sponsors Roxall Medizin GmbH
- 11 Apr 2023 New trial record